This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
We investigated the status of the apolipoprotein E allele in 538 participants in the incidence phase of the ongoing Shanghai Survey of Dementia, including 103 demented subjects, 72 with mild cognitive impairment and 363 cognitively normal. The apo E ϵ4 allele was present in 10.2% of control subjects and the allelic frequency did not change between ages 60 to 96 years. The apo E ϵ4 allelic frequency was increased both in those with Alzheimer's disease (AD) (25.4%) and those with vascular dementia (VaD)(22.2%), but not in those with other dementing illnesses or the cognitively impaired. All of the subjects homozygous for apo E ϵ4 were demented, three were diagnosed as having AD, and three met NINDS/AIREN criteria for VaD. The increased apo E ϵ4 allelic frequency in clinically diagnosed VaD patients suggests that some of the infarcts are secondary to congophilic angiopathy. The adjusted odds ratio of developing AD in this community-derived study for persons with at least one apo E ϵ4 allele was 4.1 (95% CI: 2.2, 7.7). Thus, the apo E ϵ4 risk of developing AD in this Chinese cohort is similar to that in western community studies.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Excess of serum copper not related to ceruloplasmin in Alzheimer disease
An aberrant protein complex in CSF as a biomarker of Alzheimer disease
Classification of vascular dementia in the Cardiovascular Health Study Cognition Study
The apolipoprotein E ϵ4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease